• RAMYA SRI SURA Department of Pharmacy, University College of Technology, Osmania University, Hyderabad 500007, Telangana, India
  • CVS SUBRAHMANYAM Gokaraju Rangaraju College of Pharmacy, Osmania University, Hyderabad 500090, Telangana, India
  • SHYAM SUNDER RACHAMALLA Department of Pharmacy, University College of Technology, Osmania University, Hyderabad 500007, Telangana, India



Liquisolid compacts, Nebivolol hydrochloride, Fujicalin


Objective: The aim of this study was to investigate the potential of a liquisolid system to improve the dissolution rate and the bioavailability of nebivolol hydrochloride.

Methods: Solubility of nebivolol was determined in different nonvolatile solvents to finalize the best nonvolatile vehicle having maximum solubility. The liquisolid compacts were prepared using Fujicalin as a carrier material, Aerosil 200 as a coating material, Polyethylene glycol 400 as a liquid vehicle, and Croscarmellose sodium as a super disintegrating agent. 23 full factorial design was used to optimize the formulation in which the drug concentration, PVP K 30, Excipient ratio (R), and nebivolol containing nonvolatile solvent liquid level were selected as independent variables by using design expert software. The eight liquisolid compact formulations were prepared. Nebivolol liquisolid compacts were evaluated for drug content, tablet hardness, Friability, disintegration, and dissolution. An in vivo study was carried out in male Wistar rats.

Results: The solubility of nebivolol hydrochloride in polyethylene glycol 400 was found to be greater than the other nonvolatile solvents. The liquisolid system of nebivolol was formulated successfully using Fujicalin, Aerosil 200, and polyethylene glycol 400. In vitro evaluation parameters for the liquisolid compact were within the prescribed limits. It was found that optimized liquisolid tablet formulation showed higher dissolution than the marketed tablet, with 88.33±0.94 % drug release within 120 min and the drug release was more than 75 % in 30 min for nebivolol LS-3N, which is optimized. LS-3N liquisolid compacts follow the Peppas model and exhibited first-order release.

Conclusion: The liquisolid compacts can be a promising alternative for the formulation of water-insoluble drug nebivolol hydrochloride with improved dissolution and bioavailability.


Download data is not yet available.


Patel DS, Pipaliya RM, Surti N. Liquisolid tablets for dissolution enhancement of a hypolipidemic drug. Indian J Pharm Sci. 2015;77(3):290-8. doi: 10.4103/0250-474x.159618, PMID 26180274.

Venkateswarlu K, Preethi JK, Chandrasekhar KB. Enhancement of loperamide dissolution rate by liquisolid compact technique. Adv Pharm Bull. 2016;6(3):385-90. doi: 10.15171/apb.2016.050, PMID 27766222.

Lu M, Xing H, Yang T, Yu J, Yang Z, Sun Y, Ding P. Dissolution enhancement of tadalafil by liquisolid technique. Pharm Dev Technol. 2017;22(1):77-89. doi: 10.1080/10837450.2016.1189563, PMID 27268461.

Khan AM, Agrawal SH. Formulation and evaluation of lumefantrine capsule prepared by using liquisolid technique. Int J Curr Pharm Sci. 2018;10(2):43-50. doi: 10.22159/ijcpr.2018v10i2.25836.

Rasenack N, Muller BW. Dissolution rate enhancement by in situ micronization of poorly water-soluble drugs. Pharm Res. 2002;19(12):1894-900. doi: 10.1023/a:1021410028371. PMID 12523671.

Hajare AA, Jadhav PR. Improvement of solubility and dissolution rate of indomethacin by solid dispersion in polyvinyl pyrrolidone K30 and poloxamer 188. Asian J Pharm Technol. 2012;2:116-22.

Pandey MM, Jaipal A, Charde SY, Goel P, Kumar L. Dissolution enhancement of felodipine by amorphous nanodispersions using an amphiphilic polymer: insight into the role of drug-polymer interactions on drug dissolution. Pharm Dev Technol. 2016;21(4):463-74. doi: 10.3109/10837450.2015.1022785, PMID 25777532.

Medarevic DP, Kachrimanis K, Mitric M, Djuris J, Djuric Z, Ibric S. Dissolution rate enhancement and physicochemical characterization of carbamazepine-poloxamer solid dispersions. Pharm Dev Technol. 2016;21(3):268-76. doi: 10.3109/10837450.2014.996899, PMID 25582577.

Luengo J, Aranguiz T, Sepulveda J, Hernandez L, Von Plessing C. Preliminary pharmacokinetic study of different preparations of acyclovir with beta-cyclodextrin. J Pharm Sci. 2002;91(12):2593-8. doi: 10.1002/jps.10245, PMID 12434403.

Ahmad J, Kohli K, Mir SR, Amin S. Formulation of self-nanoemulsifying drug delivery system for telmisartan with improved dissolution and oral bioavailability. J Dispers Sci Technol. 2011;32(7):958-68. doi: 10.1080/01932691.2010.488511.

Ebert WR. Soft gelatin capsules: unique dosage form. Pharm Technol. 1977;1:44-50.

Kala NP, Shastri DH, Shelat PK. Design and characterization of buccoadhesiveliquisolid system of an antihypertensive drug. J Drug Deliv. 2015;574247:1-9. doi: 10.1155/2015/574247, PMID 26579235.

Jassim ZE. Formulation and evaluation of furosemide liquisolid compact. Int J Appl Pharm. 2017;9(6):39-48. doi: 10.22159/ijap.2017v9i6.21458.

Anil AN, Thomas LI, Sudheer PR. Liquisolid compacts: an innovative approach for dissolution enhancement. Int J Pharm Pharm Sci. 2018;10(6):11-7. doi: 10.22159/ijpps.2018v10i6.25500.

Javadzadeh Y, Siahi Shadbad MR, Barzegar Jalali M, Nokhodchi A. Enhancement of dissolution rate of piroxicam using liquisolid compacts. Farmaco. 2005;60(4):361-5. doi: 10.1016/j.farmac.2004.09.005. PMID 15848213.

Rokade MA, Khandagale PR, Phadtare DI. Liquisolid compact techniques: a review. Int J Curr Pharm Sci. 2018;10(4):1-5. doi: 10.22159/ijcpr.2018v10i4.28465.

Tiong N, Elkordy AA. Effects of liquisolid formulations on dissolution of naproxen. Eur J Pharm Biopharm. 2009;73(3):373-84. doi: 10.1016/j.ejpb.2009.08.002. PMID 19679184.

Shah I, Bhatt S, Yadav A. Enhancement of solubility and dissolution of nebivolol by solid dispersion technique. Int J Pharm Pharm Sci. 2014;6(7):566-71.

GA, KB, Prasad K. Development and validation of bioanalytical HPLC method for simultaneous estimation of cilnidipine and nebivolol in human plasma. Int J Pharm Pharm Sci. 2017;9(10):253-9. doi: 10.22159/ijpps.2017v9i10.20237.

Nade VS, Kawale LA, Shendye NV, Patil NR. Protective effect of nebivolol on aluminum-induced neurobehavioral and biochemical alterations in rats. Int J Pharm Pharm Sci. 2014;6(7):386-91.

Cheng JW. Nebivolol: a third-generation beta-blocker for hypertension. Clin Ther. 2009;31(3):447-62. doi: 10.1016/j.clinthera.2009.03.007. PMID 19393838.

Moffat AC, Osselton MD, Widdop B. Clarke’s analysis of drugs and poisons in pharmaceuticals, body fluids, and postmortem material consulting. 4th ed. London: Pharmaceutical Press; 2011. p. 1760.

Nikam VJ, Patil SB. Pharmaceutical cocrystals of nebivolol hydrochloride with enhanced solubility. J Cryst Growth. 2020;534. doi: 10.1016/j.jcrysgro.2020.125488, PMID 125488.

Sipos E, Szabo ZI, Redai E, Szabo P, Sebe I, Zelko R. Preparation and characterization of nanofibrous sheets for enhanced oral dissolution of nebivolol hydrochloride. J Pharm Biomed Anal. 2016;129:224-8. doi: 10.1016/j.jpba.2016.07.004. PMID 27433987.

Jain H, Pasha TY, Bais CS, Bhandari A. Formulation and characterization of liquisolid tablets of valsartan for improvement of dissolution rate. Asian J Pharm Clin Res. 2014;7(4):21-6.

Javadzadeh Y, Musaalrezaei L, Nokhodchi A. Liquisolid technique as a new approach to sustain propranolol hydrochloride release from tablet matrices. Int J Pharm. 2008;362(1-2):102-8. doi: 10.1016/j.ijpharm.2008.06.022, PMID 18647643.ijpharm.2008.06.022.

Jaydip B, Dhaval M, Soniwala MM, Chavda J. Formulation and optimization of liquisolid compact for enhancing dissolution properties of efavirenz by using DoE approach. Saudi Pharm J. 2020;28(6):737-45. doi: 10.1016/j.jsps.2020.04.016. PMID 32550806.

Fahmy RH, Kassem MA. Enhancement of famotidine dissolution rate through liquisolid tablets formulation: in vitro and in vivo evaluation. Eur J Pharm Biopharm. 2008;69(3):993-1003. doi: 10.1016/j.ejpb.2008.02.017, PMID 18396390.

Kapoor D, Lad C, Vyas R, Patel M. Formulation development, optimization and in vitro characterization of liquisolid compacts of an oxicam derivative. J Drug Deliv Ther. 2016;6(3):64-70. doi: 10.22270/jddt.v6i3.1263.

Spireas S. Liquisolid systems and methods of preparing Same, US [patent. p. 2002]. Vol. 6(423),339 B1.

Subrahmanyam CVS. Physical pharmaceutics vallabh prakashan publishing company, editor. Vol. 1 st, Delhi; 2019. p. 83-8.

Subrahmanyam CVS, Thimmasetty J. Laboratory manual of physical. Pharmaceutics prakashan V, editor, Vol. 2 nd. Delhi; 2014. p. 24-32, 46-53.

Kamila MM, Mondal N, Ghosh LK, Gupta BK. A validated UV spectrophotometric method for estimation of nebivolol hydrochloride in bulk and pharmaceutical formulation. Pharmazie. 2007;62(7):486-7. doi: 10.1691/ph.2007.7.6259, PMID 17718186.

Dash S, Murthy PN, Nath L, Chowdhury P. Kinetic modeling on drug release from controlled drug delivery systems. Acta Pol Pharm. 2010;67(3):217-23. PMID 20524422.

Hixson AW, Crowell JH. Dependence of reaction velocity upon surface and agitation. Ind Eng Chem. 1931;23(8):923-31. doi: 10.1021/ie50260a018.

Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. Mechanisms of solute release from porous hydrophilic polymers. International Journal of Pharmaceutics. 1983;15(1):25-35. doi: 10.1016/0378-5173(83)90064-9.

Peppas NA. Analysis of fickian and non-fickian drug release from polymers. Pharm Acta Helv. 1985;60(4):110-1. PMID 4011621.

Siepmann J, Peppas NA. Higuchi equation: derivation, applications, use and misuse. Int J Pharm. 2011;418(1):6-12. doi: 10.1016/j.ijpharm.2011.03.051, PMID 21458553.

Sharma V, Pathak K. Effect of hydrogen bond formation/replacementon solubility characteristics, gastric permeation and pharmacokinetics of curcumin by application of powder solution technology. Acta Pharm Sin B. 2016;6(6):600-13. doi: 10.1016/j.apsb.2016.05.015, PMID 27818928.

Javadzadeh Y, Siahi MR, Asnaashari S, Nokhodchi A. Liquisolid technique as a tool for enhancement of poorly water-soluble drugs and evaluation of their physicochemical properties. Acta Pharm. 2007;57(1):99-109. doi: 10.2478/v10007-007-0008-6, PMID 19839410.

Shah S, Bodhe R, Gorle A. Formulation development of porous mannitol carrier: improving the dissolution of poorly soluble drugs. J Drug Delivery Ther. 2019;9(6):143-54. doi: 10.22270/jddt.v9i6.3719.

Medhi B, Prakash A. Practical manual of experimental and clinical pharmacology. 1st ed. Mumbai: Jaypee Brothers Medical Publishers Ltd; 2010. p. 24-25.

Reagan Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2008;22(3):659-61. doi: 10.1096/fj.07-9574LSF, PMID 17942826.

Zhang Y, Huo M, Zhou J, Xie S. PK Solver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in microsoft excel. Comput Methods Programs Biomed. 2010;99(3):306-14. doi: 10.1016/j.cmpb.2010.01.007. PMID 20176408.

Nair AB, Shah J, Aljaeid BM, Al-Dhubiab BE, Jacob S. Gellan gum-based hydrogel for the transdermal delivery of nebivolol: optimization and evaluation. Polymers. 2019;11(10):1699. doi: 10.3390/polym11101699, PMID 31623262.

Raj AL, Kumar YS. Preparation and evaluation of solid dispersion of nebivolol using solvent evaporation method. IJPSDR 2018;10(4). doi: 10.25004/IJPSDR.2018.100418.

Asija R, Bhatt S, Asija S, Yadav A, Shah I. Enhancement of solubility and dissolution of lercanidipine by liquisolid technique. J Chem Pharm Res. 2014;6(6):2680-6.

Vranoikovaa B, Gajdziok J. Evaluation of sorptive properties of various carriers and coating materials for liquisolid systems. Acta Pol Pharm Drug Res. 2015;72(3):539-49. PMID: 26642662.

Lu M, Xing H, Jiang J, Chen X, Yang T, Wang D, Ding P. Liquisolid technique and its applications in pharmaceutics. Asian J Pharm Sci. 2017;12(2):115-23. doi: 10.1016/j.ajps.2016.09.007.ajps.2016.09.007. PMID 32104320.

Yasmin BM, Yasmin Begum M, Alqahtani A, Ghazwani M, Alhamood NA, Hani U, Jajala A, Rahamathulla M. Development of duloxetine hydrochloride tablets for delayed and complete release using Eudragit L 100. Int J Polym Sci. 2021:1-10. doi: 10.1155/2021/8890503.

Kulkarni AS, Gaja JB. Formulation and evaluation of liquisolid compacts of diclofenac sodium. PDA J Pharm Sci Technol. 2010;64(3):222-32. PMID: 21502022.

Chella N, Shastri N, Tadikonda RR. Use of the liquisolid compact technique for improvement of the dissolution rate of valsartan. Acta Pharmaceutica Sinica B. 2012;2(5):502-8. doi: 10.1016/j.apsb.2012.07.005.

Jhaveri M, Nair AB, Shah J, Jacob S, Patel V, Mehta T. Improvement of oral bioavailability of carvedilol by liquisolid compact: optimization and pharmacokinetic study. Drug Deliv and Transl Res. 2020;10(4):975-85. doi: 10.1007/s13346-020-00734-3, PMID 32124413.

Valentine EN. Croscarmellose sodium efficiency in the development of a generic capsule formulation of piroxicam, comparable dissolution profile to the innovator product, feldene. Journal of Pharmaceutics and Drug Development 2014;1(6). doi: 10.15744/2348-9782.1.601.

Sumit RB, Harsh JT, Bhavana AP, Kunal NP, Patel MM. Formulation and evaluation of escitalopram oxalate orodispersible tablets using the sublimation technique. Int J Pharm Res Health Sci. 2018;6(2):2528-35. doi: 10.21276/ijprhs.2018.

Dholakiya A, Dudhat K, Patel J, Mori D. An integrated QbD based approach of SMEDDS and liquisolid compacts to simultaneously improve the solubility and processability of hydrochlorothiazide. J Drug Deliv Sci Technol. 2021;61. doi: 10.1016/j.jddst.2020.102162. PMID 102162.

Pradeep KCH, Venugopalaiah P, Praveen KCH, Gnanaprakash K, Gobinath M. Formulation and evaluation of mefenamic acid extended-release liquisolid tablets. Int Pharm Dev Technol. 2013;3(2):80-96.



How to Cite




Original Article(s)